About Basilea
Basilea is a company based in Basel (Switzerland) founded in 1999. It operates as a Professional Services and Licensing Model. The company has 164 employees as of December 31, 2024. Basilea offers products and services including Cresemba, Zevtera, Ceftibuten-Ledaborbactam, Fosmanogepix, and BAL2062. Basilea operates in a competitive market with competitors including Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
- Headquarter Basel, Switzerland
- Employees 164 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Basilea Pharmaceutica Ag
-
Annual Revenue
$230.19 M (USD)32.3as on Dec 31, 2024
-
Net Profit
$85.64 M (USD)642.45as on Dec 31, 2024
-
EBITDA
$71.43 M (USD)185.29as on Dec 31, 2024
-
Latest Funding Round
$6 M (USD), Grant
Feb 25, 2026
-
Investors
CARB-X
& 2 more
-
Employee Count
164
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Basilea
Basilea is a publicly listed company on the SIX with ticker symbol BSLN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Basilea
Basilea offers a comprehensive portfolio of products and services, including Cresemba, Zevtera, Ceftibuten-Ledaborbactam, Fosmanogepix, and BAL2062.
Cresemba is developed for treating fungal infections effectively.
Zevtera is formulated to combat severe bacterial infections.
Ceftibuten-Ledaborbactam is researched for oral antibiotic treatment solutions.
Fosmanogepix is advanced for novel antifungal therapy options.
BAL2062 is developed as a new antifungal treatment.
People of Basilea
Unlock access to complete
Unlock access to complete
Funding Insights of Basilea
- Total Funding Total Funding
- Total Rounds 8
- Last Round Grant — $6.0M
- First Round First Round
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2026 | Amount | Grant - Basilea | Valuation |
investors |
|
| Dec, 2024 | Amount | Grant - Basilea | Valuation |
investors |
|
| Apr, 2024 | Amount | Grant - Basilea | Valuation |
investors |
Investors in Basilea
Basilea has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include CARB-X, HBM Partners and BARDA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location | |
|
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Basilea
Financial Statements - Basilea
Basilea Comparisons
Competitors of Basilea
Basilea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule inhibitors for rare lung diseases
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| domain | founded_year | HQ Location |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| domain | founded_year | HQ Location |
Provider of human monoclonal antibodies against infectious diseases
|
|
| domain | founded_year | HQ Location |
Medical devices for brain tumor radiation therapy are provided.
|
Latest news on Basilea
Frequently Asked Questions about Basilea
Basilea was founded in 1999 and raised its 1st funding round 2 years after it was founded.
Basilea is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
As of Dec 31, 2024, the latest employee count at Basilea is 164.
Annual revenue of Basilea is $230.19M as on Dec 31, 2024.
Basilea is engaged in the development and commercialization of innovative pharmaceutical products targeting severe bacterial and fungal infections. The company operates within the healthcare sector, specializing in anti-infectives. Solutions are provided through a portfolio that includes globally recognized brands like Cresemba and Zevtera, alongside a pipeline of novel antibiotics and antifungals such as Ceftibuten-Ledaborbactam and Fosmanogepix. Research and development efforts are supported by strategic funding and partnerships to address critical medical needs of patients worldwide.
Basilea's top competitors include Imvax, Aridis Pharma and Insmed.
Basilea offers Cresemba, Zevtera, Ceftibuten-Ledaborbactam, Fosmanogepix, and BAL2062.
Yes, Basilea is publicly traded on SIX under the ticker symbol BSLN.
Basilea has 3 investors. Key investors include CARB-X, HBM Partners, and BARDA.
The ticker symbol of Basilea is BSLN on SIX.